Everest Medicines 2025: NMPA Approves IND for Cancer Vaccine EVM14
Everest Medicines, a biopharmaceutical company, announced that the Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China.
This achievement marks a key milestone in the Company's efforts to develop innovative mRNA therapeutics in oncology. First-in-human trials are expected to start in Q1 2026.
EVM14 is an off-the-shelf therapeutic mRNA cancer vaccine developed based on Everest Medicines' proprietary mRNA platform. It becomes the company's internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's NMPA and the U.S. Food and Drug Administration (FDA).
EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China.
Author's summary: Everest Medicines gets approval for cancer vaccine EVM14.